Clinical pharmacology = disease progression + drug action

Clinical pharmacology is concerned with understanding how to use medicines to treat disease. Pharmacokinetics and pharmacodynamics have provided powerful methodologies for describing the time course of concentration and effect in individuals and in populations. This population approach may also be applied to describing the progression of disease and the action of drugs to change disease progress. Quantitative models for symptomatic and disease‐modifying effects of drugs are valuable not only for describing drugs and diseases but also for identifying criteria to distinguish between types of drug actions, with implications for regulatory decisions and long‐term patient care.

[1]  M. Brin,et al.  Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.

[2]  S. Staszewski,et al.  Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside reverse transcriptase inhibitor, during 7-day monotherapy in HIV-1-infected patients , 2009, AIDS.

[3]  G. Box.  Robustness in the Strategy of Scientific Model Building. , 1979 .

[4]  Nicholas H G Holford,et al.  A Pharmacodynamic Model for the Time Course of Tumor Shrinkage by Gemcitabine + Carboplatin in Non–Small Cell Lung Cancer Patients , 2008, Clinical Cancer Research.

[5]  N. Holford,et al.  Population pharmacodynamics of romazarit. , 1995, British journal of clinical pharmacology.

[6]  V. Lobanov,et al.  An Improved Model for Disease Progression in Patients From the Alzheimer's Disease Neuroimaging Initiative , 2012, Journal of clinical pharmacology.

[7]  K E Peace,et al.  Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Nutt,et al.  Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease. , 2012, British journal of clinical pharmacology.

[9]  R Couch,et al.  Theophylline Target Concentration in Severe Airways Obstruction — 10 or 20 mg/L? , 1993, Clinical pharmacokinetics.

[10]  N. Holford,et al.  Washout and delayed start designs for identifying disease modifying effects in slowly progressive diseases using disease progression analysis , 2009, Pharmaceutical statistics.

[11]  K E Peace,et al.  Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[12]  L B Sheiner,et al.  The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. , 1984, Drug metabolism reviews.

[13]  S. Duffull,et al.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint. , 2011, British journal of clinical pharmacology.

[14]  C. Wanner,et al.  Section I. Measurement of renal function, when to refer and when to start dialysis. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  L Aarons,et al.  Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[16]  J. Nutt,et al.  Disease Progression and Pharmacodynamics in Parkinson Disease – Evidence for Functional Protection with Levodopa and Other Treatments , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[17]  Kaori Ito,et al.  Disease progression meta-analysis model in Alzheimer's disease , 2010, Alzheimer's & Dementia.

[18]  C. Wanner,et al.  Section IV. Dialysis fluid purity. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[20]  J. Nutt,et al.  Interpreting the results of Parkinson's disease clinical trials: Time for a change , 2011, Movement disorders : official journal of the Movement Disorder Society.

[21]  Lynn McFadyen,et al.  Basic PK/PD principles of drug effects in circular/proliferative systems for disease modelling , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[22]  R. D'Agostino.  The delayed-start study design. , 2009, The New England journal of medicine.

[23]  D. de Bono.  Mega-Trials , 1995, Journal of the Royal College of Physicians of London.

[24]  N. Holford,et al.  Population PKPD modelling of the long-term hypoglycaemic effect of gliclazide given as a once-a-day modified release (MR) formulation. , 2003, British journal of clinical pharmacology.

[25]  S. Papapetropoulos.  A Double-Blind, Delayed-Start Trial of Rasagiline In Parkinson's Disease , 2010 .

[26]  N. Holford.  Modeling Helps in Understanding Antidepressants , 2012, Clinical pharmacology and therapeutics.

[27]  P. Lange,et al.  Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial , 1999, The Lancet.

[28]  D. Niewoehner.  TORCH and UPLIFT: What Has Been Learned from the COPD “Mega-Trials”? , 2009, COPD.

[29]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[30]  Klaus Romero,et al.  Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[31]  N. Holford,et al.  Clinical Trial Simulation: A Review , 2010, Clinical pharmacology and therapeutics.

[32]  France Mentré,et al.  Maximum likelihood estimation of long-term HIV dynamic models and antiviral response. , 2011, Biometrics.

[33]  Nicholas H. G. Holford,et al.  Levodopa Slows Progression of Parkinson’s Disease. External Validation by Clinical Trial Simulation , 2007, Pharmaceutical Research.

[34]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[35]  O. Bärenholdt,et al.  Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen/progestin treatment , 1994, British journal of obstetrics and gynaecology.

[36]  J. Nutt,et al.  Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. , 2012, British journal of clinical pharmacology.

[37]  Meindert Danhof,et al.  Disease System Analysis: Basic Disease Progression Models in Degenerative Disease , 2005, Pharmaceutical Research.

[38]  France Mentré,et al.  The Use of Population Pharmacokinetics in Drug Development , 1996, Clinical pharmacokinetics.

[39]  A W Kelman,et al.  Population Pharmacokinetics Theory and Clinical Application , 1986, Clinical pharmacokinetics.

[40]  Lewis B. Sheiner,et al.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data , 1977, Journal of Pharmacokinetics and Biopharmaceutics.

[41]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[42]  J. Steimer,et al.  Pharmacokinetic and pharmacodynamic data and models in clinical trials , 2011, European Journal of Drug Metabolism and Pharmacokinetics.

[43]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[44]  R. Reeves,et al.  Nocebo effects with antidepressant clinical drug trial placebos. , 2007, General hospital psychiatry.

[45]  Ohidul Siddiqui,et al.  Endpoints and Analyses to Discern Disease-Modifying Drug Effects in Early Parkinson’s Disease , 2009, The AAPS Journal.

[46]  N. Holford.  A Time to Event Tutorial for Pharmacometricians , 2013, CPT: pharmacometrics & systems pharmacology.

[47]  Nick Holford.  Disease progression and neuroscience , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[48]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[49]  M. Coulthard,et al.  Human renal function maturation: a quantitative description using weight and postmenstrual age , 2009, Pediatric Nephrology.

[50]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[51]  W. Winter,et al.  A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[52]  D. Postma,et al.  Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis , 1999, Thorax.

[53]  A. Zuccalà,et al.  Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. , 1992, Kidney international.

[54]  L. Sheiner,et al.  Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.

[55]  K. Hsu,et al.  Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. , 2003, The New England journal of medicine.

[56]  D R Stanski,et al.  Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. , 1990, Anesthesiology.

[57]  L B Sheiner,et al.  Time and Theophylline Concentration Help Explain the Recovery of Peak Flow Following Acute Airways Obstruction , 1993, Clinical pharmacokinetics.

[58]  K. Kieburtz.  ADAGIO misses a beat? , 2009, The Lancet Neurology.

[59]  P. Jacqmin,et al.  A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc. , 2008, British journal of clinical pharmacology.